Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
A. Cribier, H. Eltchaninoff, C. Tron, F. Bauer, C. Agatiello, D. Nercolini, et al.
Treatment of calcific aortic stenosis UIT the percutaneous herat Valve. Mid-term follow-up from the initial feasibility studies: the French experience.
J Am Coll Cardiol, 47 (2006), pp. 1214-1223
[2.]
M. Thomas, G. Schymick, T. Walther, D. Himbert, T. Lefèvre, H. Treede, et al.
Thirty-day results of the SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) Registry. A European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve.
Circulation, 122 (2010), pp. 62-69
[3.]
J.G. Webb, D.A. Wood, J. Ye, R. Gurvitch, J.B. Masson, J. Rodés-Cabau, et al.
Transcatheter valve-in-valve implantation for failed bioprosthetic heart valves.
Circulation, 121 (2010), pp. 1848-1857
[4.]
T. Feldman, H.S. Wasserman, H.C. Herrmann, W. Gray, P.C. Block, P. Whitlow, et al.
EVEREST Studies. Percutaneous mitral valve repair using the edge-to-edge technique six-month results of the EVEREST Phase I Clinical Trial.
J Am Coll Cardiol, 46 (2005), pp. 2134-2140
[5.]
L. Mauri, P. Garg, J.M. Massaro, E. Foster, D. Glower, P. Mehoudar, et al.
The EVEREST II Trial: design and rationale for a randomized study of the evalve mitraclip system compared with mitral valve surgery for mitral regurgitation.
Am Heart J, 160 (2010), pp. 23-29
[6.]
M.C. Morice, P.W. Serruys, J.E. Sousa, J. Fajadet, E. Ban Hayashi, M. Perin, et al.
A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.
N Engl J Med, 346 (2002), pp. 1773-1780
[7.]
J.W. Moses, M.B. Leon, J.J. Popma, P.J. Fitzgerald, D.R. Holmes, C. O'Shaughnessy, et al.
Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.
N Engl J Med, 349 (2003), pp. 1315-1323
[8.]
G.W. Stone, S.G. Ellis, D.A. Cox, J. Hermiller, C. O'Shaughnessy, J.T. Mann, TAXUS IV Investigators, et al.
A Polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.
N Engl J Med, 350 (2004), pp. 221-231
[9.]
L. Mauri, E.J. Orav, R.E. Kuntz.
Late loss in lumen diameter and binary restenosis for drug-eluting stent comparison.
Circulation, 111 (2005), pp. 3435-3442
[10.]
J. Kotani, S. Nanto, T. Morozumi, et al.
Angioscopic findings of the neo-intimal coverage over the sirolimus-eluting stent: nine month follow-up study.
J Am Coll Cardiol, 47 (2006), pp. 27B
[11.]
M. Joner, A.V. Finn, A. Farb, E.K. Mont, F.D. Kolodgie, E. Ladich, et al.
Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk.
J Am Coll Cardiol, 48 (2006), pp. 193-202
[12.]
R. Moreno, C. Fernández, R. Hernández-Antolin, et al.
Drug-eluting stent thrombosis. results from a pooled analysis including 10 randomized studies.
J Am Coll Cardiol, 45 (2005), pp. 954-959
[13.]
I. Iakovou, T. Schmidt, E. Bonizzoni, et al.
Incidence, predictors and outcome of thrombosis after successful implantation of drug-eluting stents.
JAMA, 293 (2005), pp. 2126-2130
[14.]
M. Pfisterer, H.P. Brunner-LaRocca, P.T. Buser, P. Rickenbacher, P. Hunziker, C. Mueller, For the BASKET-LATE Investigators, et al.
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents.
J Am Coll Cardiol, 48 (2006), pp. 2584-2591
[15.]
C.L. Grines, R.O. Bonow, D.E. Casey Jr, T.J. Gardner, P.B. Lockhart, D.J. Moliterno, et al.
Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents. A science advisory from the AHA, ACC, SCAI, American College of Surgeons and American Dental Association.
Circulation, 115 (2007), pp. 813-818
[16.]
Y. Onuma, P.W. Serruys, N. Kukreja, S. Veldhof, J. Doostzadeh, S. Cao, et al.
Randomized comparison of everolimus and paclitaxeleluting stents: pooled analysis of the 2 year clinical follow-up from the SPIRIT II and III trials.
Eur Heart J, 31 (2010), pp. 1071-1078
[17.]
P.W. Serruys, S. Silber, S. Garg, R.J. Van Geuns, G. Richardt, P.E. Buszman, et al.
Comparison of zotarolimus-eluting and everolimus-eluting coronary stents.
N Engl J Med, 363 (2010), pp. 136-146
[18.]
R. Erbel, C. Di Mario, J. Bartunek, J. Bonnier, B. De Bruyne, F.R. Eberli, et al.
Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial.
Lancet, 369 (2007), pp. 869-875
[19.]
J.A. Ormiston, P.W. Serruys, E. Regar, D. Dudek, L. Thuesen, M.W. Webster, et al.
A bioabsorbable everolimus-eluting coronary stent systemfor patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial.
Lancet, 371 (2008), pp. 899-907
[20.]
Optical coherence tomography in cardiovascular research,
[21.]
N. Gonzalo, P.W. Serruys, E. Regar.
Optical coherence tomography: clinical applications and the evaluation of DES.
Minerva Cardioangiol, 56 (2008), pp. 511-525
[22.]
N. Gonzalo, G.J. Tearneyb, P.W. Serruys, G. Van Soest, T. Okamura, H.M. García-García, et al.
Tomografía de coherencia óptica de segunda generación en la práctica clínica. La adquisición de datos de alta velocidad muestra una reproducibilidad excelente en pacientes tratados con intervenciones coronarias percutáneas.
Rev Esp Cardiol, 63 (2010), pp. 893-903
Copyright © 2010. Sociedad Española de Arteriosclerosis y Elsevier España S.L.